Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2025
Validation of the Edmonton-33: A Patient-Reported Outcome Instrument in Head and Neck Oncology at Baseline and Subacute Phases Post-Treatment.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang K, Khan H, Seikaly H, Nichols A, Fung K, MacNeil S D, Mendez A
Аннотация
BACKGROUND: Patient-reported outcomes (PRO), which prioritize patient perspectives, are highly valuable for patient-centered care in Head and Neck Oncology. The objective of this study was to explore the longitudinal validity of the Edmonton-33 (E-33), a PRO instrument for assessing head and neck functions in swallowing, chewing, dry mouth, and speech.
METHODS: This study involved 59 adult patients (18 female, 41 male) with squamous cell carcinoma (SCC) of the oral cavity. Participants provided consent and completed the E-33 and other PRO instruments before and after surgical and radiation treatment at months 3 (n = 18), 6 (n = 18), and 9 (n = 16). Data were collected (from June 2021 to August 2024) and analyzed for correlation between domains of the E-33 and their domain-specific, previously validated counterparts before treatment (baseline) and after treatment (Months 3, 6, and 9).
RESULTS: There were statistically significant correlations (p < 0.05) between all E-33 domains and their domain-specific counterparts at baseline and at post-treatment month 6. At Months 3 and 9 post-treatment, there were partial correlations between E-33 domains and some domain-specific counterparts.
CONCLUSION: The E-33 demonstrates validity pre-treatment and post-treatment at subacute timepoint (Months 6) for capturing data on swallowing, chewing, dry mouth, and speech, similar to other previously validated instruments. This validity is limited at the more acute timepoint of 3 months post-treatment and the later timepoint of 9 months post-treatment. Additional data are needed to further explore the long-term validity at further longitudinal timepoints at 1 and 2 years post-treatment.
METHODS: This study involved 59 adult patients (18 female, 41 male) with squamous cell carcinoma (SCC) of the oral cavity. Participants provided consent and completed the E-33 and other PRO instruments before and after surgical and radiation treatment at months 3 (n = 18), 6 (n = 18), and 9 (n = 16). Data were collected (from June 2021 to August 2024) and analyzed for correlation between domains of the E-33 and their domain-specific, previously validated counterparts before treatment (baseline) and after treatment (Months 3, 6, and 9).
RESULTS: There were statistically significant correlations (p < 0.05) between all E-33 domains and their domain-specific counterparts at baseline and at post-treatment month 6. At Months 3 and 9 post-treatment, there were partial correlations between E-33 domains and some domain-specific counterparts.
CONCLUSION: The E-33 demonstrates validity pre-treatment and post-treatment at subacute timepoint (Months 6) for capturing data on swallowing, chewing, dry mouth, and speech, similar to other previously validated instruments. This validity is limited at the more acute timepoint of 3 months post-treatment and the later timepoint of 9 months post-treatment. Additional data are needed to further explore the long-term validity at further longitudinal timepoints at 1 and 2 years post-treatment.